UR9A Stock Overview
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Clinuvel Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$7.85 |
| 52 Week High | AU$11.20 |
| 52 Week Low | AU$7.70 |
| Beta | 0.85 |
| 11 Month Change | -9.25% |
| 3 Month Change | -1.26% |
| 1 Year Change | -19.49% |
| 33 Year Change | -56.15% |
| 5 Year Change | -53.80% |
| Change since IPO | -52.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| UR9A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.9% | -0.7% | -0.02% |
| 1Y | -19.5% | -17.2% | 8.2% |
Return vs Industry: UR9A underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: UR9A underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| UR9A volatility | |
|---|---|
| UR9A Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: UR9A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: UR9A's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Philippe Wolgen | www.clinuvel.com |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
Clinuvel Pharmaceuticals Limited Fundamentals Summary
| UR9A fundamental statistics | |
|---|---|
| Market cap | €406.45m |
| Earnings (TTM) | €22.24m |
| Revenue (TTM) | €55.03m |
18.3x
P/E Ratio7.4x
P/S RatioIs UR9A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UR9A income statement (TTM) | |
|---|---|
| Revenue | AU$88.18m |
| Cost of Revenue | AU$7.73m |
| Gross Profit | AU$80.45m |
| Other Expenses | AU$44.81m |
| Earnings | AU$35.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.71 |
| Gross Margin | 91.23% |
| Net Profit Margin | 40.41% |
| Debt/Equity Ratio | 0% |
How did UR9A perform over the long term?
See historical performance and comparison